Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck

Kim, J G; Sohn, Sang Kyun; Kim, D H; Baek, Jin Ho; Jeon, Soeun; Chae, Yee Soo; Lee, K B; Park, J S; Sohn, Jin Ho; Kim, J C; Park, I K

doi:10.1038/sj.bjc.6602849

Cited by 23 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two phase II studies have been reported with capecitabine (administered at doses of 825 mg m À2 (Kim et al, 2005) and 2000 mg m À2 (Hitt et al, 2004) on days 1 -14) in combination with cisplatin (doses of 75 -80 mg m À2 on day 1) every 21 days. Kim et al (2005) studied the capecitabine/cisplatin combination in 37 patients with locally advanced stage. The results observed (CR of 78.4%, PR of 16.2% and 2-year OS of 57.9%) were comparable with those reported in most chemoradiotherapy studies.…”

Section: Discussionmentioning

confidence: 99%

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

Martínez‐Trufero

Isla

Adansa³

et al. 2010

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: Platinum-based therapy (PBT) is the standard therapy for recurrent and/or metastatic head and neck cancer (HNC), but the incidence of recurrence remains high. This study evaluates the efficacy and tolerability of capecitabine as palliative monotherapy for recurrent HNC previously treated with PBT. METHODS: Patients aged 18 -75 years, with Eastern Cooperative Oncology Group performance status 0 -2, squamous HNC with locoregional and/or metastatic recurrence previously treated with PBT and adequate organ functions, were included. Capecitabine (1.250 mg m À2 BID) was administered on days 1 -14 every 21 days for at least two cycles. RESULTS: A total of 40 male patients with a median age of 58 years were analysed. All patients received a median number of four cycles of capecitabine (range: 1 -9) and the median relative dose intensity was 91%. Seven patients were not evaluable for response. Overall response rate was 24.2%. Median time to progression and overall survival were 4.8 and 7.3 months, respectively. Haematological adverse events (AEs) grade 3/4 were reported in six patients. Most common grade 3/4 non-haematological AEs were asthenia (12.5%), palmar-plantar eritrodisestesia (10%), mucositis (10%), dysphagia (10%) and diarrhoea (7.5%). CONCLUSIONS: Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

Martínez‐Trufero

Isla

Adansa³

et al. 2010

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The 2 drugs have nonoverlapping toxicity profiles. The combination of Cap and cisplatin (CapCisp) as a palliative regimen has been efficiently used in many solid tumors, especially in squamous cell carcinoma of the head and neck (SCCHN) and in carcinoma of the gastrointestinal and genitourinary system, with predictable toxicity [8][9][10][11][12][13] . To evaluate the activity and toxicity of the combination of CapCisp in anthracycline-and taxane-pretreated MBC patients was the aim of our study.…”

Section: Introductionmentioning

confidence: 99%

Capecitabine and Cisplatin Combination Is an Active and Well-Tolerated Doublet in the Treatment of Metastatic Breast Carcinoma Patients Pretreated with Anthracycline and Taxanes

Öksüzoğlu

Abalı²,

Hayran³

et al. 2008

Chemotherapy

View full text Add to dashboard Cite

Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients. Thirty-three patients, 20–61 years of age (median 41), were included. They received Cap 2,000 mg/m² on days 1–14 and Cisp 60 mg/m² on day 1, repeated every 3 weeks. Twelve nonprogressive patients continued single-agent Cap therapy until progression or until intolerable toxicity after Cisp cessation. The disease control rate in 154 cycles was 81.8%: complete response 3.0% (n = 1), partial response 48.5% (n = 16) and stable disease 30.3% (n = 10). The median time to disease progression was 6.3 months (95% CI 3.8–8.8). The median overall survival was 11.5 months (95% CI 6.9–16.1). The only grade 3 toxicity was neutropenia, observed in 4 patients (12.1%). CapCisp has an encouraging anti-tumor activity with a low toxicity rate in anthracycline- and taxane-pretreated metastatic breast cancer patients.

show abstract

“…A number of prospective studies have also shown the efficacy and favorable safety profile of capecitabine as a radiosensitizer over other commonly used chemotherapeutic agents like cisplatin and 5-FU when treating many solid tumors, including head and neck cancer (11)(12)(13)(14)17,(19)(20)(21)24). The overall survival and progression-free survival rate in these studies at 2 years were 76.8% and 57.9%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Capecitabine has been widely used in the treatment of breast, stomach, and cervix cancer as well as other solid tumors (11,(13)(14)(15)(16)19,20). Several studies have demonstrated that concurrent chemoradiotherapy using capecitabine, with a dose ranging from 800 to 825 mg/m 2 , in combination with cisplatin or oxaliplatin is effective and has a low toxicity profile in the neoadjuvant setting of rectal cancer or locally advanced esophageal cancer (12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

“…There is evidence that radiation leads to the upregulation of thymidine phosphorylase expression, thereby synergizing the action of capecitabine (9). Mounting evidence suggests that oral capecitabine, which mimics continuous 5-FU infusion, has substantial activity in squamous cell carcinoma of the head and neck (10,11) and is replacing 5-FU in the treatment of many solid tumors as well as in advanced head and neck squamous cell carcinoma (12)(13)(14)(15)(16)(17)(18)(19)(20). Thus, the impact of radiation-induced toxicity on quality of life and treatment compliance justifies the use of concurrent chemoradiotherapy with an oral capecitabinebased regimen.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer

Gupta

Khan²,

Barik³

et al. 2013

Drug Discov Ther

View full text Add to dashboard Cite

We aimed to assess the efficacy and safety of concurrent capecitabine and cisplatin over concurrent cisplatin and 5-flurouracil (5-FU) in locally advanced squamous cell carcinoma of the head and neck. One hundred and fifty-three patients (all of whom had stage III or IV unresectable disease with no distant metastases and who had received two cycles of taxol and cisplatin chemotherapy) were randomly assigned to receive either concurrent cisplatin (75 mg/m 2 in day 1 and 2) and 5-FU (750 mg/m 2 in day 1, 2, and 3) from the first day of radiotherapy at an interval of 3 weeks (Arm I) or cisplatin (75 mg/m 2 in day 1 and 2) and capecitabine (750 mg/m 2 in two divided doses from day 1-14) from the first day of radiotherapy at a 3-week interval (Arm II). Results showed that patients in Arm II had a significantly better rate of complete response, fewer nodes, and better overall response compared to those in Arm I. The two groups had a similar 3-year disease-free survival, progressionfree survival, and overall survival, i.e. they did not differ significantly. Variables indicating the quality of life of the two groups were compared. Patients in Arm II had a significantly higher quality of life compared to those in Arm I. The two groups had similar treatment-related acute and late toxicity, i.e. they did not differ significantly. These results have thoroughly substantiated the contention that concurrent chemoradiation with capecitabine and cisplatin may be regarded as an effective and welltolerated regimen in the treatment of the patients with locally advanced head and neck cancer.

show abstract

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck

Cited by 23 publications

References 28 publications

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

Capecitabine and Cisplatin Combination Is an Active and Well-Tolerated Doublet in the Treatment of Metastatic Breast Carcinoma Patients Pretreated with Anthracycline and Taxanes

Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer

Contact Info

Product

Resources

About